Rock Springs Capital Management LP Acquires 414,203 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Rock Springs Capital Management LP grew its holdings in NewAmsterdam Pharma (NASDAQ:NAMS) by 117.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 767,522 shares of the company’s stock after purchasing an additional 414,203 shares during the period. Rock Springs Capital Management LP’s holdings in NewAmsterdam Pharma were worth $19,725,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of NAMS. National Bank of Canada FI bought a new position in NewAmsterdam Pharma in the fourth quarter valued at about $51,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. KLP Kapitalforvaltning AS bought a new position in NewAmsterdam Pharma in the 4th quarter valued at approximately $154,000. Barclays PLC raised its holdings in NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the last quarter. Finally, HB Wealth Management LLC acquired a new stake in NewAmsterdam Pharma during the 4th quarter worth approximately $224,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 14th. Needham & Company LLC restated a “buy” rating and set a $42.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a research report on Monday, March 3rd. Finally, Scotiabank boosted their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a research report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, NewAmsterdam Pharma has an average rating of “Buy” and a consensus target price of $43.33.

Insider Transactions at NewAmsterdam Pharma

In other news, CAO Louise Frederika Kooij sold 150,000 shares of the company’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the transaction, the chief accounting officer now owns 15,000 shares of the company’s stock, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James N. Topper purchased 4,005 shares of the business’s stock in a transaction dated Tuesday, March 4th. The shares were purchased at an average price of $21.02 per share, with a total value of $84,185.10. Following the purchase, the director now directly owns 3,012,434 shares in the company, valued at $63,321,362.68. This trade represents a 0.13 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Price Performance

NASDAQ NAMS opened at $16.34 on Monday. The business’s fifty day moving average is $19.87 and its 200-day moving average is $21.27. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -6.28 and a beta of -0.01. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to analyst estimates of $3.30 million. Research analysts expect that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.